Comprehensive multi-attribute method workflow for biotherapeutic characterization and current good manufacturing practices testing

Silvia Millán-Martín, Craig Jakes, Sara Carillo, Richard Rogers, Da Ren, Jonathan Bones

Published: 2022-12-15 DOI: 10.1038/s41596-022-00785-5

LC-MS

Multi-attribute method

Biotherapeutic characterization

Good manufacturing practices

Protein quality attributes

AI 解读

Supplementary information

Supplementary Information

Supplementary Figs. 1–4 and Table 1

Supplementary Data 1

Data processing walk-through details

Supplementary Data 2

SST report obtained for Hypersil Gold 150 × 2.1-mm, 3-µm column, including all evaluated parameters and monitored quality attributes

Supplementary Data 3

SST report obtained for Acclaim C18, 250 × 2.1-mm, 2.2-µm column, including all evaluated parameters and monitored quality attributes

Generation of mouse–human chimeric embryos

Genome-wide quantification of transcription factor binding at single-DNA-molecule resolution using methyl-transferase footprinting

Generation of CRISPR–Cas9-mediated genetic knockout human intestinal tissue–derived enteroid lines by lentivirus transduction and single-cell cloning

A puromycin-dependent activity-based sensing probe for histochemical staining of hydrogen peroxide in cells and animal tissues

Decoding personal biotic and abiotic airborne exposome

A clinically relevant model of focal embolic cerebral ischemia by thrombus and thrombolysis in rhesus monkeys

Bioengineering human intestinal mucosal grafts using patient-derived organoids, fibroblasts and scaffolds

Biomimetic tail-to-head terpene cyclizations using the resorcin[4]arene capsule catalyst

Neuroscience robotics for controlled induction and real-time assessment of hallucinations

Scanorama: integrating large and diverse single-cell transcriptomic datasets

Single-cell RNA sequencing (scRNA-seq)（单细胞RNA测序）

Data integration（数据集成）

Heterogeneity（异质性）

查看全部

Sections

Figures

References

Supplementary information

Yasunaga, M. Antibody therapeutics and immunoregulation in cancer and autoimmune disease. Semin. Cancer Biol. 64, 1–12 (2020).
Shim, H. Bispecific antibodies and antibody-drug conjugates for cancer therapy: technological considerations. Biomolecules 10, 360 (2020).
Shu, S. A., Wang, J., Tao, M. H. & Leung, P. S. Gene therapy for autoimmune disease. Clin. Rev. Allergy Immunol. 49, 163–176 (2015).
Islam, M. A., Kundu, S. & Hassan, R. Gene therapy approaches in an autoimmune demyelinating disease: multiple sclerosis. Curr. Gene Ther. 19, 376–385 (2020).
World Preview 2018, Outlook to 2024. Evaluate Pharma, 1–47 Available at http://www.evaluate.com/thought-leadership/pharma/evaluatepharma-world-preview-2018-outlook-2024?gclid=Cj0KCQiAmaibBhCAARIsAKUlaKTZfRwuRaj58cikLdbczZL8vgBdGJpJX2DJ2GQKWpFuGn8BKbN9ZWAaAm8OEALw_wcB (2018).
Mullard, A. FDA approves 100th monoclonal antibody product. Nat. Rev. Drug Discov. 20, 491–495 (2021).
Jefferis, R. Posttranslational modifications and the immunogenicity of biotherapeutics. J. Immunol. Res. 2016, 5358272 (2016).
Xu, Y. et al. Structure, heterogeneity and developability assessment of therapeutic antibodies. MAbs 11, 239–264 (2019).
Virág, D. et al. Current trends in the analysis of post‑translational modifications. Chromatographia 83, 1–10 (2020).
Graf, T. et al. Recent advances in LC-MS based characterization of protein-based bio-therapeutics - mastering analytical challenges posed by the increasing format complexity. J. Pharm. Biomed. Anal. 186, 113251 (2020).
Rogstad, S. et al. A retrospective evaluation of the use of mass spectrometry in FDA biologics license applications. J. Am. Soc. Mass Spectrom. 28, 786–794 (2017).
Apostol, I. et al. Enabling development, manufacturing, and regulatory approval of biotherapeutics through advances in mass spectrometry. Curr. Opin. Biotehcnol. 71, 206–215 (2021).
Rogers, R. S. et al. Development of a quantitative mass spectrometry multi-attribute method for characterization, quality control testing and disposition of biologics. MAbs 7, 881–890 (2015).
Rogers, R. S. et al. A view on the importance of “multi-attribute method” for measuring purity of biopharmaceuticals and improving overall control strategy. AAPS J. 20, 7 (2018).
Xu, W. et al. A quadrupole Dalton-based multi-attribute method for product characterization, process development, and quality control of therapeutic proteins. MAbs 9, 1186–1196 (2017).
Rogstad, S. et al. Multi-attribute method for quality control of therapeutic proteins. Anal. Chem. 91, 14170–14177 (2019).
Buettner, A., Maier, M., Bonnington, L., Bulau, P. & Reusch, D. Multi-attribute monitoring of complex erythropoetin beta glycosylation by GluC liquid chromatography-mass spectrometry peptide mapping. Anal. Chem. 92, 7574–7580 (2020).
Liu, Y. et al. Simultaneous monitoring and comparison of multiple product quality attributes for cell culture processes at different scales using a LC/MS/MS based multi-attribute method. J. Pharm. Sci. 109, 1–11 (2020).
Ren, D. Advancing mass spectrometry technology in cGMP environments. Trends Biotechnol. 38, 1051–1053 (2020).
Sokolowska, I. et al. Implementation of a high-resolution liquid chromatography-mass spectrometry method in quality control laboratories for release and stability testing of a commercial antibody product. Anal. Chem. 92, 2369–2373 (2020).
Tajiri-Tsukada, M., Hashii, N. & Ishii-Watabe, A. Establishment of a highly precise multi-attribute method for the characterization and quality control of therapeutic monoclonal antibodies. Bioengineered 11, 984–1000 (2020).
Zhang, Z., Chan, P. K., Richardson, J. & Shah, B. An evaluation of instrument types for mass spectrometry-based multi-attribute analysis of biotherapeutics. MAbs 12, 1783062 (2020).
Mouchahoir, T. et al. New peak detection performance metrics from the MAM Consortium Interlaboratory Study. J. Am. Soc. Mass Spectrom. 32, 913–928 (2021).
Song, Y. E. et al. Automated mass spectrometry multi-attribute method analyses for process development and characterization of mAbs. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 1166, 122540 (2021).
Evans, A. R., Hebert, A. S., Mulholland, J., Lewis, M. J. & Hu, P. ID-MAM: a validated identity and multi-attribute monitoring method for commercial release and stability testing of a bispecific antibody. Anal. Chem. 93, 9166––9173 (2021).
Jakes, C. et al. Tracking the behavior of monoclonal antibody product quality attributes using a multi-attribute method workflow. J. Am. Soc. Mass Spectrom. 32, 1998–2012 (2021).
Atouf, F., Chess, E. & McCarthy, D. Shaping tomorrow’s solutions to today’s biologics quality challenges. USP Biologics Open Forum, April 28, 2021. Available at http://www.usp.org/get-involved/provide-input/stakeholder-forums/bio-mam (2021).
Liu, Y. et al. A fully integrated online platform for real time monitoring of multiple product quality attributes in biopharmaceutical processes for monoclonal antibody therapeutics. J. Pharm. Sci. 111, 358–367 (2022).
Melmer, M. et al. HILIC analysis of fluorescence-labeled N-glycans from recombinant biopharmaceuticals. Anal. Bioanal. Chem. 398, 905–914 (2010).
Fekete, S., Beck, A., Veuthey, J. L. & Guillarme, D. Ion-exchange chromatography for the characterization of biopharmaceuticals. J. Pharm. Biomed. Anal. 113, 43–55 (2015).
Rustandi, R. R., Washabaugh, M. W. & Wang, Y. Applications of CE SDS gel in development of biopharmaceutical antibody-based products. Electrophoresis 29, 3612–3620 (2008).
Wang, Y. et al. Simultaneous monitoring of oxidation, deamidation, isomerization, and glycosylation of monoclonal antibodies by liquid chromatography-mass spectrometry method with ultrafast tryptic digestion. MAbs 8, 1477–1486 (2016).
Wang, T. et al. Application of a quantitative LC-MS multiattribute method for monitoring site-specific glycan heterogeneity on a monoclonal antibody containing two N-linked glycosylation sites. Anal. Chem. 89, 3562–3567 (2017).
Bomans, K. et al. Multi-attribute monitoring of antibody modifications by semi-automated liquid chromatography mass spectrometry peptide mapping. Am. Pharm. Rev. Available at http://www.americanpharmaceuticalreview.com/Featured-Articles/331529-Multi-Attribute-Monitoring-of-Antibody-Modifications-by-Semi-Automated-Liquid-Chromatography-Mass-Spectrometry-Peptide-Mapping/ (2016).
Ogata, Y. et al. eAutomated multi-attribute method sample preparation using high-throughput buffer exchange tips. Rapid Commun. Mass Spectrom. 36, e9222. (2021).
Hao, Z. et al. Multi-attribute method performance profile for quality control of monoclonal antibody therapeutics. J. Pharm. Biomed. Anal. 205, 114330 (2021).
Dong, J. et al. High-throughput, automated protein A purification platform with multiattribute LC-MS analysis for advanced cell culture process monitoring. Anal. Chem. 88, 8673–8679 (2016).
Millán-Martín, S. et al. Inter-laboratory study of an optimised peptide mapping workflow using automated trypsin digestion for monitoring monoclonal antibody product quality attributes. Anal. Bioanal. Chem. 412, 6833–6848 (2020).
Arndt, J. R. et al. High-resolution ion-mobility-enabled peptide mapping for high-throughput critical quality attribute monitoring. J. Am. Soc. Mass Spectrom. 32, 2019–2032 (2021).
Jakes, C. et al. Consistent results for peptide mapping and monitoring across three systems of the Vanquish UHPLC platform (AN-001123). Thermo Fisher Scientific Available at http://www.thermofisher.com/es/en/home/products-and-services/promotions/industrial/simplify-biopharma-hr-mam-workflow.html (2022).
Qian, C., Niu, B., Jimenez, R. B., Wang, J. & Albarghouthi, M. Fully automated peptide mapping multi-attribute method by liquid chromatography-mass spectrometry with robotic liquid handling system. J. Pharm. Biomed. Anal. 198, 113988 (2021).
Rogers, R., Swenson, S., Khuu-Duong, K. & Zhang, T. Mass spectrometry-based process analytical technologies for cell therapies. MAM Consortium Available at http://mamconsortium.org/ (2021).
Carillo, S., Criscuolo, A., Fussl, F., Cook, K. & Bones, J. Intact multi-attribute method (iMAM): a flexible tool for the analysis of monoclonal antibodies. Eur. J. Pharm. Biopharm. 177, 241–248 (2022).
Yu, L. X. et al. Understanding pharmaceutical quality by design. AAPS J. 16, 771–783 (2014).
Zhang, Y. & Yang, H. Bringing Multi-Attribute Method (MAM) to the next level. ASMS 2021, Pennsylvania Convention Center (November 2021). Available at http://www.asms.org/publications/abstracts-and-proceedings (2021).
Yang, H. et al. The MAM 2.0 workflow enables seamless transition from research and development to quality control (AN000463). Thermo Fisher Scientific Available at http://www.thermofisher.com/es/en/home/products-and-services/promotions/industrial/simplify-biopharma-hr-mam-workflow.html (2022).
Robinson, C. J. & Jones, C. Quality control and analytical techniques for biopharmaceuticals. Bioanalysis 3, 81–95 (2011).
Beck, A., Wagner-Rousset, E., Ayoub, D., Van Dorsselaer, A. & Sanglier-Cianferani, S. Characterization of therapeutic antibodies and related products. Anal. Chem. 85, 715–736 (2013).
Berkowitz, S. A., Engen, J. R., Mazzeo, J. M. & Jones, G. B. Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. Nat. Rev. Drug Discov. 11, 527–540 (2012).
Zhang, X., Chemmalil, L., Ding, J., Mussa, N. & Li, Z. Imaged capillary isoelectric focusing in native condition: a novel and successful example. Anal. Biochem. 537, 13–19 (2017).
Zhang, L. et al. Characterization and elimination of artificial non-covalent light Chain dimers in reduced CE-SDS analysis of pertuzumab. J. Pharm. Biomed. Anal. 190, 113527 (2020).
Esterman, A. L., Katiyar, A. & Krishnamurthy, G. Implementation of USP antibody standard for system suitability in capillary electrophoresis sodium dodecyl sulfate (CE-SDS) for release and stability methods. J. Pharm. Biomed. Anal. 128, 447–454 (2016).
Fekete, S., Guillarme, D., Sandra, P. & Sandra, K. Chromatographic, electrophoretic, and mass spectrometric methods for the analytical characterization of protein biopharmaceuticals. Anal. Chem. 88, 480–507 (2016).
Zhu-Shimoni, J. et al. Host cell protein testing by ELISAs and the use of orthogonal methods. Biotechnol. Bioeng. 111, 2367–2379 (2014).
EMA. ICH Topic Q 6 B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. Available at http://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-6-b-test-procedures-acceptance-criteria-biotechnological/biological-products-step-5_en.pdf (1999).
Sitasuwan, P. et al. Enhancing the multi-attribute method through an automated and high-throughput sample preparation. MAbs 13, e1978131 (2021).
Dong, M. W. Tryptic mapping by reversed phase liquid chromatography. Adv. Chromatogr. 32, 21–51 (1992).
Cho, I. H. et al. Evaluation of the structural, physicochemical, and biological characteristics of SB4, a biosimilar of etanercept. MAbs 8, 1136–1155 (2016).
Stavenhagen, K. et al. Site-specific N- and O-glycosylation analysis of atacicept. MAbs 11, 1053–1063 (2019).
Guapo, F., Strasser, L., Millán-Martín, S., Anderson, I. & Bones, J. Fast and efficient digestion of adeno associated virus (AAV) capsid proteins for liquid chromatography mass spectrometry (LC-MS) based peptide mapping and post translational modification analysis (PTMs). J. Pharm. Biomed. Anal. 207, 1–7 (2021).
Toole, E. N. et al. Rapid highly-efficient digestion and peptide mapping of adeno-associated viruses. Anal. Chem. 93, 10403–10410 (2021).
Ren, D. et al. An improved trypsin digestion method minimizes digestion-induced modifications on proteins. Anal. Biochem. 392, 12–21 (2009).
Zhou, M., Gucinski, A. C. & Boyne, M. T. 2nd Performance metrics for evaluating system suitability in liquid chromatography—Mass spectrometry peptide mass mapping of protein therapeutics and monoclonal antibodies. MAbs 7, 1104–1117 (2015).
FDA. Part 11, Electronic Records; Electronic Signatures - Scope and Application. Guidance for Industry. (September 2003). Available at http://www.fda.gov/regulatory-information/search-fda-guidance-documents/part-11-electronic-records-electronic-signatures-scope-and-application (2003).
Mesmin, C., Manache-Alberici, L. & Jones, J. Validation of LC-MS Multi-Attribute Method (MAM) Supporting Biopharma Process Characterization. Available at http://www.biopharminternational.com/view/validation-lc-ms-multi-attribute-method-mam-supporting-biopharma-process-characterization (2020).
Rogers, R. Case Study: Automated Software-Driven Implementation of the Multi-Attribute Method (MAM) for Biotherapeutic Characterization. Available at http://www.genedata.com/fileadmin/4.Resources/Case-studies/Ex_Just_MAM_19E03.pdf (2019).
Dong, Q. et al. The NISTmAb tryptic peptide spectral library for monoclonal antibody characterization. MAbs 10, 354–369 (2018).
Schiel, J. E., Davis, D. L. & Borisov, O. V. State-of-the-Art and Emerging Technologies for Therapeutic Monoclonal Antibody Characterization Volume 2. Biopharmaceutical Characterization: The NISTmAb Case Study. ACS Symposium Series. Vol. 1201 Available at http://pubs.acs.org/doi/10.1021/bk-2015-1201 (2015).
Mouchahoir, T., Rogers, R. & Schiel, J. Interlaboratory performance metrics from the MAM Consortium New Peak Detection Round Robin Study. 15th Symposium on the Practical Applications of Mass Spectrometry in the Biotechnology Industry (San Francisco, CA) Available at http://www.nist.gov/publications/new-peak-detection-performance-metrics-mam-consortium-interlaboratory-study (2018).
Rogers, R. MS in QC: a single multi-attribute method for quality control and release testing of biologics. CASSS MS, Boston, 24 September 2013.
Yandrofski, K. et al. Interlaboratory studies using the NISTmAb to advance biopharmaceutical structural analytics. Front. Mol. Biosci. 9, 876780 (2022).